BlackRock’s NervGen Pharma NGEN Stock Holding History

BlackRock’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15.8K	Buy	+8,257	New	+$15.8K	﹤0.01%	5508

Other funds holding NGEN

Valley Forge Investment Consultants Audubon, Pennsylvania $405M AUM 13.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

PFG Investments Woodbury, New York $2.64B AUM 26.11% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $67.2B AUM 18.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

BlackRock's NGEN Position: Q3 2026 in Review

BlackRock opened a new position in NervGen Pharma (NGEN) in Q3 2026: 8,257 shares worth $15.8K. The stake represents ﹤0.01% of the portfolio and ranks #5508 among its holdings.

49 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.

BlackRock held 8,257 shares of NervGen Pharma worth $15.8K as of Q3 2026.
NervGen Pharma was a new BlackRock position in Q3 2026.
NervGen Pharma made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5508 holding.
49 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.